As expected, the benefit in terms of median PFS and OS time positively correlated with the rate of ER+ breast cancer cells and the type of response to hormone therapy; in fact, it was significantly better in those with higher ER+ rate and more in responding patients than in those in stable disease during hormone-immunotherapy (117, 138). This evidence concerns the gene ESR1 and breast carcinoma.